Literature DB >> 34221833

Long-term survival after multidisciplinary treatments for advanced esophagogastric junction cancer.

Chihiro Matsumoto1, Masaaki Iwatsuki1, Takeshi Morinaga1, Kohei Yamashita1, Kenichi Nakamura1, Junji Kurashige1, Kojiro Eto1, Shiro Iwagami1, Yoshifumi Baba1, Naoya Yoshida1, Yuji Miyamoto1, Hideo Baba1.   

Abstract

Stage IV Gastric/Esophagogastric junction cancer (G/EGJ) has an unfavorable prognosis and poor curability. In this study, we report the case of long-term survival after multidisciplinary treatments for advanced esophagogastric junction cancer. A 53-year-old male patient was diagnosed with HER2 positive advanced esophagogastric junction cancer and mediastinal and paraaortic lymph node metastasis. After systemic chemotherapy for 1 year, minimally invasive esophagectomy was conducted as conversion surgery. However, peritoneal and liver metastasis was observed on 3 months after curative surgery. 2 years after operation, solitary brain metastasis was detected and stereotactic radiosurgery (SRS) using a gamma knife was underwent. After 1 year, despite the continuous administration of Nivolumab, the paraaortic lymph node increased in size again and radiation therapy was conducted. Currently, he is alive and undergoing chemotherapy. © The Japan Society of Clinical Oncology 2021.

Entities:  

Keywords:  Conversion surgery; Immune checkpoint inhibitors; Multidisciplinary treatments; Oligometastasis

Year:  2021        PMID： 34221833      PMCID： PMC8206417          DOI： 10.1007/s13691-021-00480-4

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN： 2192-3183


  21 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  Oligometastases.

Authors:  S Hellman; R R Weichselbaum
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

3.  Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer.

Authors:  Shuhei Ito; Eiji Oki; Yuichiro Nakashima; Koji Ando; Yukiharu Hiyoshi; Kippei Ohgaki; Hiroshi Saeki; Masaru Morita; Yoshihisa Sakaguchi; Yoshihiko Maehara
Journal:  Anticancer Res       Date:  2015-01       Impact factor: 2.480

4.  Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Authors:  Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman
Journal:  Lancet       Date:  2018-01-31       Impact factor: 79.321

5.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

6.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

Authors:  Narikazu Boku; Seiichiro Yamamoto; Haruhiko Fukuda; Kuniaki Shirao; Toshihiko Doi; Akira Sawaki; Wasaburo Koizumi; Hiroshi Saito; Kensei Yamaguchi; Hiroya Takiuchi; Junichiro Nasu; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2009-10-07       Impact factor: 41.316

Review 7.  Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis.

Authors:  Sheraz R Markar; Sameh Mikhail; George Malietzis; Thanos Athanasiou; Christophe Mariette; Mitsuru Sasako; George B Hanna
Journal:  Ann Surg       Date:  2016-06       Impact factor: 12.969

8.  Risk Factors for Recurrence After Curative Conversion Surgery for Unresectable Gastric Cancer.

Authors:  Minoru Fukuchi; Toru Ishiguro; Kyoichi Ogata; Akiharu Kimura; Youichi Kumagai; Keiichiro Ishibashi; Hideyuki Ishida; Hiroyuki Kuwano; Erito Mochiki
Journal:  Anticancer Res       Date:  2015-11       Impact factor: 2.480

9.  Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry.

Authors:  Atsushi Nashimoto; Kohei Akazawa; Yoh Isobe; Isao Miyashiro; Hitoshi Katai; Yasuhiro Kodera; Shunichi Tsujitani; Yasuyuki Seto; Hiroshi Furukawa; Ichiro Oda; Hiroyuki Ono; Satoshi Tanabe; Michio Kaminishi
Journal:  Gastric Cancer       Date:  2012-06-23       Impact factor: 7.370
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.